{
    "xml": "<topic id=\"PHP5670\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/peginterferon-alfa\" basename=\"peginterferon-alfa\" title=\"PEGINTERFERON ALFA\">\n<title>PEGINTERFERON ALFA</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_959\" namespace=\"/interactions/list-of-drug-interactions/interferons/peginterferon-alfa\">Peginterferon Alfa</xref>\n</p>\n<data name=\"vtmid\">398841009</data>\r\n<data name=\"vtmid\">129477009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_998292074\" title=\"Interferons\">Interferons</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP60434\" outputclass=\"drugAction\" rev=\"1.7\" parent=\"/drugs/peginterferon-alfa\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Polyethylene glycol-conjugated (&#8216;pegylated&#8217;) derivatives of interferon alfa (<b>peginterferon alfa-2a</b> and <b>peginterferon alfa-2b</b>) are available; pegylation increases the persistence of the interferon in the blood.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60453\" outputclass=\"contraindications\" rev=\"1.15\" parent=\"/drugs/peginterferon-alfa\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p>For contra-indications consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60473\" outputclass=\"cautions\" rev=\"1.11\" parent=\"/drugs/peginterferon-alfa\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>For cautions consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60382\" outputclass=\"interactions\" rev=\"1.14\" parent=\"/drugs/peginterferon-alfa\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (interferons).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60311\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/peginterferon-alfa\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anorexia</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">influenza-like symptoms</ph>; <ph outputclass=\"sideEffect\">lethargy</ph>; <ph outputclass=\"sideEffect\">nausea</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">arrhythmias</ph>; <ph outputclass=\"sideEffect\">cardiovascular problems</ph>; <ph outputclass=\"sideEffect\">coma (usually with high doses in the elderly)</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">hyperglycaemia</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypertriglyceridaemia (sometimes severe)</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">myelosuppression (particularly affecting granulocyte counts)</ph>; <ph outputclass=\"sideEffect\">nephrotoxicity</ph>; <ph outputclass=\"sideEffect\">ocular side-effects</ph>; <ph outputclass=\"sideEffect\">palpitation</ph>; <ph outputclass=\"sideEffect\">psoriasiform rash</ph>; <ph outputclass=\"sideEffect\">seizures (usually with high doses in the elderly)</ph>; <ph outputclass=\"sideEffect\">suicidal behaviour</ph>; <ph outputclass=\"sideEffect\">thyroid abnormalities</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For information on side effects consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60466\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/peginterferon-alfa\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Effective contraception required during treatment&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60362\" outputclass=\"pregnancy\" parent=\"/drugs/peginterferon-alfa\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in <i>animal</i> studies).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60482\" outputclass=\"breastFeeding\" parent=\"/drugs/peginterferon-alfa\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturers advise avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60411\" outputclass=\"hepaticImpairment\" parent=\"/drugs/peginterferon-alfa\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Close monitoring required in mild to moderate hepatic impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60339\" outputclass=\"renalImpairment\" parent=\"/drugs/peginterferon-alfa\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose in moderate to severe impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>For information on peginterferon alfa use in renal impairment consult product literature.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>Close monitoring required in renal impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60252\" outputclass=\"monitoringRequirements\" parent=\"/drugs/peginterferon-alfa\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitoring of lipid concentration is recommended.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60202\" outputclass=\"nationalFunding\" rev=\"1.26\" parent=\"/drugs/peginterferon-alfa\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA200</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010)</p>\r\n<p>The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (&#8216;watchful waiting&#8217;). Peginterferon alfa alone can be used if ribavirin is contra-indicated or not tolerated.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA200\">www.nice.org.uk/TA200</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA200</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010)</p>\r\n<p>The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years:</p>\r\n<ul>\r\n<li>not previously treated with interferon alfa or peginterferon alfa;</li>\r\n<li>treated previously with interferon alfa alone or in combination with ribavirin;</li>\r\n<li>whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;</li>\r\n<li>co-infected with HIV.</li>\r\n</ul>\r\n<p>Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA200\">www.nice.org.uk/TA200</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5670-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/peginterferon-alfa\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75253\" title=\"Solution for injection\" namespace=\"/drugs/peginterferon-alfa/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75246\" title=\"Powder and solvent for solution for injection\" namespace=\"/drugs/peginterferon-alfa/powder-and-solvent-for-solution-for-injection\">Powder and solvent for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78120\" namespace=\"/treatment-summaries/respiratory-syncytial-virus\" title=\"Respiratory syncytial virus\" count=\"2\" rel=\"backlink\">Respiratory syncytial virus</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78240\" namespace=\"/treatment-summaries/hepatitis\" title=\"Hepatitis\" count=\"12\" rel=\"backlink\">Hepatitis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_959\" namespace=\"/interactions/list-of-drug-interactions/interferons/peginterferon-alfa\" title=\"Peginterferon Alfa\" count=\"1\" rel=\"link\">Peginterferon Alfa</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75253\" namespace=\"/drugs/peginterferon-alfa/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75246\" namespace=\"/drugs/peginterferon-alfa/powder-and-solvent-for-solution-for-injection\" title=\"Powder and solvent for solution for injection\" count=\"1\" rel=\"link\">Powder and solvent for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP5670",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/peginterferon-alfa",
    "basename": "peginterferon-alfa",
    "title": "PEGINTERFERON ALFA",
    "interactants": [
        {
            "id": "bnf_int_959",
            "label": "Peginterferon Alfa"
        }
    ],
    "vtmid": "129477009",
    "drugClassification": [
        "Interferons"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Polyethylene glycol-conjugated (&#8216;pegylated&#8217;) derivatives of interferon alfa (peginterferon alfa-2a and peginterferon alfa-2b) are available; pegylation increases the persistence of the interferon in the blood.",
                "html": "<p>Polyethylene glycol-conjugated (&#8216;pegylated&#8217;) derivatives of interferon alfa (<b>peginterferon alfa-2a</b> and <b>peginterferon alfa-2b</b>) are available; pegylation increases the persistence of the interferon in the blood.</p>"
            }
        ]
    },
    "contraindications": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For contra-indications consult product literature.",
                "html": "<p>For contra-indications consult product literature.</p>"
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For cautions consult product literature.",
                "html": "<p>For cautions consult product literature.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (interferons).",
                "html": "<p>Appendix 1 (interferons).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Anorexia",
                        "html": "Anorexia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "influenza-like symptoms",
                        "html": "influenza-like symptoms",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "lethargy",
                        "html": "lethargy",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arrhythmias",
                        "html": "arrhythmias",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cardiovascular problems",
                        "html": "cardiovascular problems",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "coma (usually with high doses in the elderly)",
                        "html": "coma (usually with high doses in the elderly)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperglycaemia",
                        "html": "hyperglycaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertriglyceridaemia (sometimes severe)",
                        "html": "hypertriglyceridaemia (sometimes severe)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myelosuppression (particularly affecting granulocyte counts)",
                        "html": "myelosuppression (particularly affecting granulocyte counts)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nephrotoxicity",
                        "html": "nephrotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ocular side-effects",
                        "html": "ocular side-effects",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "palpitation",
                        "html": "palpitation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "psoriasiform rash",
                        "html": "psoriasiform rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "seizures (usually with high doses in the elderly)",
                        "html": "seizures (usually with high doses in the elderly)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "suicidal behaviour",
                        "html": "suicidal behaviour",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thyroid abnormalities",
                        "html": "thyroid abnormalities",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "For information on side effects consult product literature.",
                "html": "<p>For information on side effects consult product literature.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Effective contraception required during treatment&#8212;consult product literature.",
                "html": "<p>Effective contraception required during treatment&#8212;consult product literature.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in animal studies).",
                "html": "<p>Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in <i>animal</i> studies).</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturers advise avoid&#8212;no information available.",
                "html": "<p>Manufacturers advise avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe impairment.",
                "html": "<p>Avoid in severe impairment.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Close monitoring required in mild to moderate hepatic impairment.",
                "html": "<p>Close monitoring required in mild to moderate hepatic impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose in moderate to severe impairment.",
                "html": "<p>Reduce dose in moderate to severe impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "For information on peginterferon alfa use in renal impairment consult product literature.",
                "html": "<p>For information on peginterferon alfa use in renal impairment consult product literature.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Close monitoring required in renal impairment.",
                "html": "<p>Close monitoring required in renal impairment.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitoring of lipid concentration is recommended.",
                "html": "<p>Monitoring of lipid concentration is recommended.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA200",
                        "label": "www.nice.org.uk/TA200"
                    }
                ],
                "fundingIdentifier": "NICE TA200",
                "textContent": "Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010) The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (&#8216;watchful waiting&#8217;). Peginterferon alfa alone can be used if ribavirin is contra-indicated or not tolerated.\n\nwww.nice.org.uk/TA200",
                "html": "<p outputclass=\"title\">Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010)</p> <p>The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (&#8216;watchful waiting&#8217;). Peginterferon alfa alone can be used if ribavirin is contra-indicated or not tolerated.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA200\">www.nice.org.uk/TA200</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA200",
                        "label": "www.nice.org.uk/TA200"
                    }
                ],
                "fundingIdentifier": "NICE TA200",
                "textContent": "Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010) The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years: not previously treated with interferon alfa or peginterferon alfa; treated previously with interferon alfa alone or in combination with ribavirin; whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed; co-infected with HIV. Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.\n\nwww.nice.org.uk/TA200",
                "html": "<p outputclass=\"title\">Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010)</p> <p>The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years:</p> <ul> <li>not previously treated with interferon alfa or peginterferon alfa;</li> <li>treated previously with interferon alfa alone or in combination with ribavirin;</li> <li>whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;</li> <li>co-infected with HIV.</li> </ul> <p>Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA200\">www.nice.org.uk/TA200</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75253",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75246",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78120",
                "label": "Respiratory syncytial virus",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78240",
                "label": "Hepatitis",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_959",
                "label": "Peginterferon Alfa",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75253",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75246",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}